Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

ConferenceTransCon CNPPositive

AI Analysis

Summary

Ascendis Pharma announced an oral presentation of Week 104 data from its pivotal ApproaCH Trial of TransCon CNP (navepegritide) at the ISDS 2026 annual meeting in Toronto. The presentation will showcase long-term efficacy and safety data for the once-weekly treatment in children with achondroplasia.

Clinical Trial Data

Phase

pivotal

Outcome Details

Week 104 data from pivotal ApproaCH Trial presented at ISDS 2026

Importance:5/10

Sentiment:

0.30

achondroplasiaconference presentationlong-term dataTransCon CNP

Related Companies

$ASND

Read the original article

Published by GlobeNewswire Clinical Studies on August 25, 2026 8:01 PM

Read Original